Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibiotic strategy could shorten hospital stays for heart infections

NCT ID NCT07550595

Not yet recruiting Disease control Sponsor: Kirby Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests a long-acting antibiotic called oritavancin for treating gram-positive heart infections, such as infective endocarditis. The goal is to see if weekly IV doses can replace the usual weeks-long hospital stays and daily antibiotics. The study will enroll 20 adults and compare standard dosing with dosing guided by drug level monitoring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Oritavancin (an antibiotic given by IV)
What this could lead to
If successful, this could offer a shorter, more convenient antibiotic treatment for serious heart infections, potentially reducing hospital stays and improving access for people who inject drugs.
What could go wrong
This is a small, early-phase pilot study with only 20 participants, so results may not apply broadly. Oritavancin is not yet approved for heart infections, and optimal dosing is still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC DEVICE INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocarditis gram-positive bacterial infections infective endocarditis prosthesis-related infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC DEVICE INFECTION GRAM-POSITIVE BACTERIAL INFECTIONS INFECTIVE ENDOCARDITIS

Contacts and locations

Locations

  • Prince of Wales Hospital

    Sydney, New South Wales, 2031, Australia

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, 2050, Australia

  • St Vincent's Hospital

    Sydney, New South Wales, 2010, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.